Driehaus Capital Management LLC filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing that its beneficial ownership of Cue Biopharma, Inc. common stock had dropped to 4.02% as of September 30, 2026.
Key Highlights
- Triggering event date: The filing reports September 30, 2026 as the date of the event requiring this amended statement.
- Beneficial ownership: Driehaus Capital Management LLC reported aggregate beneficial ownership of 292,144 shares of Cue Biopharma, Inc. common stock.
- Percent of class: Those shares represent 4.02% of the outstanding class, according to the filing.
- Below 5% threshold: The filing states, "Driehaus Capital Management LLC has ceased being a beneficial owner of more than 5% of Cue Biopharma, Inc."
- Voting and dispositive power: The filer reported zero sole voting power and zero sole dispositive power, with shared voting and shared dispositive power each covering all 292,144 shares.
- Filer organization: Driehaus Capital Management LLC is organized in Delaware and lists its principal business office at 25 East Erie Street, Chicago, Illinois 60611.
Driehaus Capital Management Reports Reduced Stake in Cue Biopharma
Driehaus Capital Management LLC submitted Amendment No. 1 to its Schedule 13G regarding its holdings in Cue Biopharma, Inc. (NASDAQ:CUE), whose principal executive offices are located at 40 Guest Street, Boston, MA 02135. The amendment was signed by Janet McWilliams, General Counsel, and dated November 16, 2026, with the event triggering the filing occurring on September 30, 2026.
According to the filing, Driehaus Capital Management LLC beneficially owns 292,144 shares of Cue Biopharma common stock, representing 4.02% of the class. The filer reported no sole voting power and no sole dispositive power over any of these shares, while disclosing shared voting power and shared dispositive power of 292,144 shares each. The filing identifies the CUSIP number for the common stock as 22978P205.
The filer checked Item 5, "Ownership of 5 Percent or Less of a Class," and noted in its filing that it "has ceased being a beneficial owner of more than 5% of Cue Biopharma, Inc." The filing certifies that the securities were acquired and are held in the ordinary course of business, and were not acquired or held for the purpose of changing or influencing control of the issuer.
What Was Disclosed
Driehaus Capital Management LLC filed an amended Schedule 13G disclosing a 4.02% beneficial ownership position of 292,144 shares of Cue Biopharma, Inc. common stock as of September 30, 2026, noting it had fallen below the 5% ownership threshold.



Please wait processing your request...